+1803294983432
customer.service@microbix.com
Antigen Products
For over three decades, Microbix has been a leading antigen supplier with one of the most comprehensive ranges of infectious disease antigens at a commercial scale.
Childhood Disease Antigens
Microbix continues to serve as a trusted native antigen supplier for IVD industry leaders specializing in childhood disease immunological test development. Our native antigens are purified and inactivated to eliminate infectivity while maintaining antigenicity, ensuring utmost safety and satisfaction for end-users. Our comprehensive antigen panel covers rubella, varicella-zoster, P3H3 cell extract, EBV Viral Capsid Ag pure and concentrated, measles, and mumps, supporting robust assay development for childhood disease testing..
Dengue Antigens
Microbix’s dengue panel covers all four serotypes (DENV-1, DENV-2, DENV-3, DENV-4), designed both for use in assays to detect the presence of antibodies against dengue virus and as a positive control for the presence of dengue antigens in a sample. These products are formulated in a buffer that should not interfere with conjugation chemistries that are typically used in immunoassay development. Using the Microbix native dengue virus enables superior detection of all dengue proteins in diagnostic testing.
ToRCH Antigens
ToRCH infections (including toxoplasmosis and other (varicella-zoster virus), rubella virus, cytomegalovirus, and herpes simplex) virus), are common etiologic agents of congenital abnormalities. Microbix’s highly stable, specific, and sensitive native antigens are derived from purified and inactivated whole viruses produced in cell culture. Our trusted antigens are used by diagnostic companies around the world to design a variety of immunoassays used in ToRCH screening.
Respiratory Antigens
Microbix’s respiratory antigen product panel covers adenovirus, respiratory syncytial virus (RSV), parainfluenza 2 & 3, Mycoplasma pneumoniae, influenza A & B, and Chlamydophila pneumoniae. As diagnostic companies continue to improve the speed and technology of their tests, they increasingly depend on high-quality antigens to drive innovation and development. Microbix’s antigens are inactivated to eliminate infectivity while maintaining antigenicity, ensuring both optimal diagnostic performance and maximum laboratory safety.
Other Antigens
Microbix’s infectious disease antigen portfolio supports the detection of globally significant pathogens, including Borrelia burgdorferi and rotavirus Grade 3. Formulated for use in immunodiagnostic assays to detect the presence of antibodies against these diseases and as a positive control, these native antigens are purified and inactivated to eliminate infectivity while preserving antigenic integrity. This ensures high diagnostic accuracy alongside enhanced biosafety, supporting reliable test results.
STI Antigens
Microbix’s STI antigen panel includes Chlamydophila trachomatis and Herpes Simplex Virus types 1 and 2, which are among the most common pathogens associated with sexually transmitted infections. These native antigens are purified and inactivated to eliminate infectivity while preserving antigenic integrity. This ensures the accuracy and reliability needed for the development of immunodiagnostic tests.
Download Our Full Product Catalogue
Frequently Asked Questions
Are your antigen products available in different formats?
- All antigen production takes place in liquid formulations. Depending on the product type, they are available for order in 1mL, 10mL, 50mL, and 100mL.
- Our rubella products are available as 1mg, 5 mg, 10 mg, 25 mg, and 50 mg.
Are your antigens for research use only, or can they be used for clinical purposes?
Our antigens are intended for research use only or for further manufacturing use (e.g., raw material use).
How are your antigen products stored and shipped to ensure stability?
To maintain stability following antigen production, our products are stored at temperatures ranging from -70°C to -100°C and shipped in containers with dry ice.
Are the antigens derived from natural sources or produced synthetically?
Our antigens are derived from natural sources.
What is the shelf life of your antigen products?
Our antigen products have a guaranteed shelf life of two years from the shipping date.
Testimonials
Microbix Proudly Supports Over 100+ Customers with Leading Diagnostic Solutions
Learn more about how our clients worldwide use our product lines to enhance the way they do business.
We considered other external quality controls but selected Microbix QAPs as the best solution to support assay optimization and to significantly simplify QC procedures with minimal to no pipetting steps. Microbix’s technical expertise, product design, performance, and superior customer service are impressive. We look forward to continuing our collaboration.
Robert Martinez, VP of Business Development & Scientific Affairs
We were looking for a set of controls that fully covered the range of high-risk HPV types and Microbix is the only company to have such a portfolio. After an extensive evaluation process, we concluded the performance of Microbix QAPs are exactly what Ulisse needs and the interactions with their team are delightful.
Bruna Marini, COO
MDx testing for HPV improves cervical cancer screening by identifying those at-risk efficiently. Close monitoring of the entire HPV testing workflow is critical to realizing this healthcare goal and Microbix’s HPV QAPs have been selected to support the quality assessment monitoring of the molecular testing process, a vital part of BVO’s quality management system
Dr. Rob Schuurman, National Reference Officer for the Dutch Cervical Cancer Screening Program (BVO)
r-Biopharm is pleased that the program will be delivering world-class diagnostic testing to some of the most remote populations in Australia. It has been a privilege to work with the program’s operational team and Microbix to integrate the use of the best possible test and test-workflow controls into the program
Andreas Simons, Director, Project Management Clinical Diagnostics
We’re pleased to be employing Microbix’s innovative QAPs for this new and important EQA program. Genital ulcers are the cause of a considerable and growing burden of disease that can only be alleviated by way of accurate diagnosis and treatment
Juha Wahlstedt, Sales Director at Labquality
Microbix approached us before the pandemic started, and the relationship developed so easily and quickly that we formalized our collaboration in 2020. Along with their excellent technical capabilities, they have successfully developed relationships with many diagnostics manufacturers around the world. We are pleased that our FLOQSwabs® are their exclusive choice for their growing line of swab formatted QAPs™.
Gaetano Natale, Chief Commercial Officer.
We’ve been using Microbix’s External Quality controls for 3 years specifically from their Respiratory and Sexually Transmitted Infections panels on our instruments. It has helped us ensure accurate and reliable patient results and we’ve been delighted with their performance.
Alfie Zhen Fang, Buyer, Procurement
Your Reliable Source for Antigen Products
Microbix’s viral, bacterial, and parasitic products are used in a wide range of immunodiagnostic assays, including ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry. They are also applied as controls for diagnostic assays and basic and applied research in virology, microbiology, cell biology, immunology, and pathology. Additionally, these antigens support vaccine and antiviral research and development efforts.
Our antigen panels include ToRCH antigens, respiratory antigens, childhood disease antigens, sexually transmitted Infections antigens, dengue antigens, and more.
Diagnostic companies around the world rely on Microbix’s high-quality antigens to develop a variety of immunoassays for a broad range of screening.
Speak to a Customer Service Representative
Let our knowledgeable experts help you secure your products today.
News & Insights from Our Diagnostics Experts
Microbix Schedules Release of Results for Q1 Fiscal 2026
Microbix announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its first quarter of fiscal 2026 ended December 31, 2025 (“Q1 2026”) pr...
Microbix Presents Molecular Pathology Platform Results
Microbix announces that it is presenting results of its novel Quality Assessment Products (“QAPs™”) and platform technology for supporting the quality management and reproducibility of Molecular Pathology...
Microbix Updates Investor Presentation on its Website
Microbix announces that it has updated the investor presentation on its corporate website in response to comments of staff of the Ontario Securities Commission (OSC & OSC Staff) in relation to its usage of earn...
